Welcome to our dedicated page for Bio-Techne SEC filings (Ticker: TECH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Bio-Techne Corporation filings document the formal disclosure record for a Minnesota life sciences company that sells reagents, analytical instruments and precision diagnostics. Recent Form 8-K reports furnish quarterly and annual operating results, financial condition updates and cash dividend announcements, with exhibits containing the related earnings and dividend releases.
Governance filings include definitive proxy materials and annual meeting vote results covering board size and director elections. Other current reports disclose executive leadership changes and employment arrangements for segment management, tying corporate governance disclosures to Bio-Techne's diagnostics, spatial biology and analytical solutions operations.
Bio-Techne director Amy E. Herr reported routine equity activity on 02/03/2026, mainly involving awards held by her significant other. On that date, 38 restricted stock units converted into 38 shares of common stock at $0, all held indirectly through her significant other.
To cover withholding obligations, 16 indirectly held common shares were disposed of at $64.63 per share, leaving 2,176 common shares indirectly held by her significant other and 2,680 shares held directly. The filing also lists multiple stock options and additional restricted stock units with vesting dates from 2026 through 2035, all either directly held or indirectly held through her significant other.
Bio‑Techne reported essentially flat revenue but stronger profits for the quarter ended December 31, 2025. Net sales were $295.9 million versus $297.0 million a year earlier, while net earnings rose to $38.0 million from $34.9 million. Diluted EPS increased to $0.24 from $0.22.
GAAP gross margin slipped to 64.6% from 65.3%, and adjusted gross margin fell to 68.5% from 70.5%, mainly from product mix. Selling, general and administrative expenses declined 6% to $113.7 million as cost management and restructuring took hold.
The Protein Sciences segment grew sales 2% to $215.1 million but saw lower margins, while Diagnostics and Spatial Biology reported a 4% sales decline to $81.2 million but a much stronger 10.4% operating margin, helped by the Exosome Diagnostics divestiture and efficiency initiatives. Operating cash flow was $110.0 million for the six months, and debt under the credit facility fell to $260.0 million.
Bio‑Techne reported essentially flat revenue but stronger profits for the quarter ended December 31, 2025. Net sales were $295.9 million versus $297.0 million a year earlier, while net earnings rose to $38.0 million from $34.9 million. Diluted EPS increased to $0.24 from $0.22.
GAAP gross margin slipped to 64.6% from 65.3%, and adjusted gross margin fell to 68.5% from 70.5%, mainly from product mix. Selling, general and administrative expenses declined 6% to $113.7 million as cost management and restructuring took hold.
The Protein Sciences segment grew sales 2% to $215.1 million but saw lower margins, while Diagnostics and Spatial Biology reported a 4% sales decline to $81.2 million but a much stronger 10.4% operating margin, helped by the Exosome Diagnostics divestiture and efficiency initiatives. Operating cash flow was $110.0 million for the six months, and debt under the credit facility fell to $260.0 million.
Bio-Techne Corporation reported that it issued a press release on February 4, 2026 describing its results of operations for the quarter and six months ended December 31, 2025 and its financial condition as of that date. The company also issued a separate press release on the same day announcing a cash dividend, which is attached as another exhibit.
Bio-Techne Corporation reported that it issued a press release on February 4, 2026 describing its results of operations for the quarter and six months ended December 31, 2025 and its financial condition as of that date. The company also issued a separate press release on the same day announcing a cash dividend, which is attached as another exhibit.
Bio-Techne Corp President – Diag & Spatial Bio, Matthew McManus, reported equity award activity in company stock. On February 1, 2026, 4,621 restricted stock units converted into the same number of common shares at $0 per share. On the same date, 1,665 common shares were withheld at $64.09 per share to cover obligations, leaving 7,691 common shares held directly.
McManus continues to hold multiple equity awards, including performance restricted stock units and stock options that vest over several future dates and run through expiration dates up to August 15, 2035. Each restricted stock unit represents a contingent right to receive one share of Bio-Techne common stock.
Bio‑Techne (TECH) Chief Executive Officer and Director Kim Kelderman reported an insider transaction. On 11/03/2025, he disposed of 2,303 shares of common stock at $62.57 under transaction code F, and now directly holds 48,665 shares.
The filing also lists multiple derivative awards outstanding, including stock options and restricted stock units. Examples include stock options covering 90,441 shares at an exercise price of $53.60 expiring on 08/15/2035, and performance RSUs covering 70,708 shares subject to performance-based vesting.
Bio‑Techne (TECH) Chief Executive Officer and Director Kim Kelderman reported an insider transaction. On 11/03/2025, he disposed of 2,303 shares of common stock at $62.57 under transaction code F, and now directly holds 48,665 shares.
The filing also lists multiple derivative awards outstanding, including stock options and restricted stock units. Examples include stock options covering 90,441 shares at an exercise price of $53.60 expiring on 08/15/2035, and performance RSUs covering 70,708 shares subject to performance-based vesting.
Bio-Techne (TECH) reported insider transactions by its CFO on 11/03/2025. The executive acquired company stock through RSU vesting and surrendered shares to cover taxes.
Two RSU conversions (code M) added 13,159 shares and 11,545 shares at $0. A tax withholding transaction (code F) disposed of 11,865 shares at $62.57. Following these transactions, the CFO directly owned 142,722 shares.
These actions reflect routine equity award vesting and associated tax settlement rather than an open‑market purchase or sale.
Bio-Techne (TECH) reported insider transactions by its CFO on 11/03/2025. The executive acquired company stock through RSU vesting and surrendered shares to cover taxes.
Two RSU conversions (code M) added 13,159 shares and 11,545 shares at $0. A tax withholding transaction (code F) disposed of 11,865 shares at $62.57. Following these transactions, the CFO directly owned 142,722 shares.
These actions reflect routine equity award vesting and associated tax settlement rather than an open‑market purchase or sale.
Bio‑Techne (TECH) reported an insider equity event by its President, Protein Sciences. On 11/03/2025, 9,911 shares were acquired at $0 upon settlement of restricted stock units, followed by the disposition of 4,520 shares at $62.57, typically associated with tax withholding. After these transactions, the officer directly owned 20,503 common shares.
The filing also lists outstanding equity awards, including stock options with expirations through 2035 and various time- and performance-based RSUs, indicating future vesting schedules tied to service and performance conditions.
Bio‑Techne (TECH) reported an insider equity event by its President, Protein Sciences. On 11/03/2025, 9,911 shares were acquired at $0 upon settlement of restricted stock units, followed by the disposition of 4,520 shares at $62.57, typically associated with tax withholding. After these transactions, the officer directly owned 20,503 common shares.
The filing also lists outstanding equity awards, including stock options with expirations through 2035 and various time- and performance-based RSUs, indicating future vesting schedules tied to service and performance conditions.
Bio‑Techne (TECH) reported Q1 FY2026 results. Net sales were $286.6 million versus $289.5 million a year ago as Protein Sciences softened while Diagnostics & Spatial Biology improved organically. Gross margin rose to 65.6% from 63.2%, and operating income increased to $47.7 million from $40.0 million. Net earnings were $38.2 million with diluted EPS of $0.24, up from $0.21.
Cash flow from operations was $27.6 million. Cash and equivalents were $145.0 million, and long‑term debt decreased to $300.0 million from $346.0 million, reflecting $46.0 million in repayments. Segment detail: Protein Sciences sales were $202.2 million (down 1%), operating margin 38.4%; Diagnostics & Spatial Biology sales were $79.5 million (down 4% reported; organic growth 3%), operating margin 11.2% versus 5.1%. The quarter included a $6.8 million recovery related to the Exosome Diagnostics divestiture and receipt of MDxHealth stock valued at $8.7 million. EMEA (ex‑UK) grew, while the United States declined year over year.
Bio‑Techne (TECH) reported Q1 FY2026 results. Net sales were $286.6 million versus $289.5 million a year ago as Protein Sciences softened while Diagnostics & Spatial Biology improved organically. Gross margin rose to 65.6% from 63.2%, and operating income increased to $47.7 million from $40.0 million. Net earnings were $38.2 million with diluted EPS of $0.24, up from $0.21.
Cash flow from operations was $27.6 million. Cash and equivalents were $145.0 million, and long‑term debt decreased to $300.0 million from $346.0 million, reflecting $46.0 million in repayments. Segment detail: Protein Sciences sales were $202.2 million (down 1%), operating margin 38.4%; Diagnostics & Spatial Biology sales were $79.5 million (down 4% reported; organic growth 3%), operating margin 11.2% versus 5.1%. The quarter included a $6.8 million recovery related to the Exosome Diagnostics divestiture and receipt of MDxHealth stock valued at $8.7 million. EMEA (ex‑UK) grew, while the United States declined year over year.
Bio‑Techne Corporation filed an 8‑K reporting that it issued a press release describing results of operations for the quarter ended September 30, 2025 and its financial condition as of that date. The company also announced via a separate press release that its Board declared a cash dividend.
Shareholders held the Annual Meeting with a quorum of 140,827,559 shares, representing approximately 90.45% of outstanding shares. Shareholders set the number of directors at nine (For 140,278,598; Against 314,005; Abstain 234,956), and elected all nine nominees by a majority standard. The advisory vote on executive compensation passed (For 100,792,824; Against 39,025,321; Abstain 1,009,414). Shareholders ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026 (For 137,578,559; Against 3,055,503; Abstain 193,497).
Bio‑Techne Corporation filed an 8‑K reporting that it issued a press release describing results of operations for the quarter ended September 30, 2025 and its financial condition as of that date. The company also announced via a separate press release that its Board declared a cash dividend.
Shareholders held the Annual Meeting with a quorum of 140,827,559 shares, representing approximately 90.45% of outstanding shares. Shareholders set the number of directors at nine (For 140,278,598; Against 314,005; Abstain 234,956), and elected all nine nominees by a majority standard. The advisory vote on executive compensation passed (For 100,792,824; Against 39,025,321; Abstain 1,009,414). Shareholders ratified KPMG LLP as independent registered public accounting firm for the fiscal year ending June 30, 2026 (For 137,578,559; Against 3,055,503; Abstain 193,497).
Bio-Techne Corp (TECH) reported an insider equity transaction by a director. On 10/30/2025, the reporting person acquired 1,640 shares of common stock at $0 and received a grant of stock options for 3,777 shares at an exercise price of $60.96, expiring on 10/30/2035.
After these transactions, the director directly beneficially owns 8,775 shares of common stock. The option grant vests on the earlier of the one year anniversary of the grant date (10/30/2025) or the date of Bio-Techne's 2026 annual meeting of shareholders.